Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // September 28th, 2010 // 6:55 am
Hello, everyone, and top of the morning of to you. The skies are gray over the Pharmalot corporate campus but our spirits are sunny. We hope yours are as well. Meanwhile, as we hustle one of the short people off to the schoolhouse, here are a few tidbits to help you start the day. May it be productive and remunerative. See you soon…
Endo Pharma Pays $1.2B For Qualitest (Associated Press)
FDA Panel Will Review Gardasil For Anal Cancer (Federal Register)
Sanofi Patents On Taxotere Are Invalidated (Bloomberg News)
EU Begins Safety Review Of Bisphosphanates (PharmaTimes)
Pfizer Ends Sutent Study For Prostate Cancer (Reuters)
Glaxo Asks FDA To Withdraw Smokeless Tobacco Products (Wall Street Journal)
Novo Nordisk To Challenge Anti-Trust Charge In Russia (Moscow Times)
Lilly Invests $1.2B In US-Russia Research Program (PharmaTimes)
Former Merck CEO Donates $50M To Columbia (Bloomberg News)
Sanofi Pays $60M For VaxDesign (PharmaTimes)
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Bisphosophonates, Columbia University, Eli Lilly, European Union, GlaxoSmithKline, Merck, Patents, Pfizer, Prostate Cancer, Roy Vagelos, Russia, Sanofi Aventis, Sutent, Taxotere, Tobacco, VaxDesign